靶向严重急性呼吸系统综合症冠状病毒2的人工microRNAs设计与思考

动植物人工miRNAs(artificial miRNAs,amiRNAs)在抗病毒感染中发挥重要作用。然而,有关amiRNAs靶向抑制重症急性呼吸综合征冠状病毒2(severe acute respiratory syndrome coronavirus 2,SARS-CoV-2)的相关研究未见报道。目的:本研究旨在设计靶向SARS-CoV-2的amiRNAs,进一步分析amiRNAs对不同变异株的匹配程度。方法:利用Invitrogen Block-iT RNAi Designer成功设计靶向SARS-CoV-2的amiRNAs。结果:分别命名为amiR-Cov23utr-1、2、3、4;其中amiR-Cov23utr-1、3和4在Omicron BA.5/2022中靶向区域序列十分保守;amiR-Cov23utr-2在Omicron BA.5/2022中的靶点缺失。结论:本研初步设计和分析了靶向SARS-CoV-2的amiRNAs,为后续深入研究amiRNAs抗SARS-CoV-2感染提供了重要基础资料。

MicroRNAs as potential biomarkers for diagnosis of schizophrenia and influence of antipsychotic treatment

Chara cterized by positive symptoms(such as changes in behavior or thoughts,including delusions and hallu cinations),negative symptoms(such as apathy,anhedonia,and social withdrawal),and cognitive impairments,schizophrenia is a chro nic,severe,and disabling mental disorder with late adolescence or early adulthood onset,Antipsychotics are the most commonly used drugs to treat schizophrenia,but those currently in use do not fully reverse all three types of symptoms characte rizing this condition.Schizophrenia is frequently misdiagnosed,resulting in a delay of or inappropriate treatment.Abnormal expression of microRNAs is connected to brain development and disease and could provide novel biomarkers for the diagnosis and prognosis of schizophrenia.The recent studies reviewed included microRNA profiling in blood-and urine-based materials and nervous tissue mate rials.From the studies that had validated the preliminary findings,potential candidate biomarkers for schizophrenia in adults could be miR-22-3p,-30e-5p,-92a-3p,-148b-5p,-181a-3p,-181a-5p,-181b-5p,-199 b-5p,-137 in whole blood,and miR-130b,-193a-3p in blood plasma.Antipsychotic treatment of schizophrenia patients was found to modulate the expression of certain microRNAs including miR-130b,-193a-3p,-132,-195,-30e,-432 in blood plasma.Further studies are warranted with adolescents and young adults having schizophrenia and consideration should be given to using animal models of the disorder to investigate the effect of suppressing or overexpressing specific microRNAs.

MicroRNAs in thyroid cancer with focus on medullary thyroid carcinoma:potential therapeutic targets and diagnostic/prognostic markers and web based tools

This review aimed to describe the inculpation of microRNAs(miRNAs)in thyroid cancer(TC)and its subtypes,mainly medullary thyroid carcinoma(MTC),and to outline web-based tools and databases for bioinformatics analysis of miRNAs in TC.Additionally,the capacity of miRNAs to serve as therapeutic targets and biomarkers in TC management will be discussed.This review is based on a literature search of relevant articles on the role of miRNAs in TC and its subtypes,mainly MTC.Additionally,web-based tools and databases for bioinformatics analysis of miRNAs in TC were identified and described.MiRNAs can perform as oncomiRs or antioncoges,relying on the target mRNAs they regulate.MiRNA replacement therapy using miRNA mimics or antimiRs that aim to suppress the function of certain miRNAs can be applied to correct miRNAs aberrantly expressed in diseases,particularly in cancer.MiRNAs are involved in the modulation of fundamental pathways related to cancer,resembling cell cycle checkpoints and DNA repair pathways.MiRNAs are also rather stable and can reliably be detected in different types of biological materials,rendering them favorable diagnosis and prognosis biomarkers as well.MiRNAs have emerged as promising tools for evaluating medical outcomes in TC and as possible therapeutic targets.The contribution of miRNAs in thyroid cancer,particularly MTC,is an active area of research,and the utility of web applications and databases for the biological data analysis of miRNAs in TC is becoming increasingly important.

MicroRNAs in inflammatory bowel disease:What do we know and what can we expect?

MicroRNAs(miRNAs),small non-coding RNAs composed of 18–24 nucleotides,are potent regulators of gene expression,contributing to the regulation of more than 30%of protein-coding genes.Considering that miRNAs are regulators of inflammatory pathways and the differentiation of intestinal epithelial cells,there is an interest in exploring their importance in inflammatory bowel disease(IBD).IBD is a chronic and multifactorial disease of the gastrointestinal tract;the main forms are Crohn's disease and ulcerative colitis.Several studies have investigated the dysregulated expression of miRNAs in IBD,demonstrating their important roles as regulators and potential biomarkers of this disease.This editorial presents what is known and what is expected regarding miRNAs in IBD.Although the important regulatory roles of miRNAs in IBD are clearly established,biomarkers for IBD that can be applied in clinical practice are lacking,emphasizing the importance of further studies.Discoveries regarding the influence of miRNAs on the inflammatory process and the exploration of their role in gene regulation are expected to provide a basis for the use of miRNAs not only as potent biomarkers in IBD but also as therapeutic targets for the control of inflammatory processes in personalized medicine.

MicroRNAs:A novel signature in the metastasis of esophageal squamous cell carcinoma

Esophageal squamous cell carcinoma(ESCC)is a malignant epithelial tumor,characterized by squamous cell differentiation,it is the sixth leading cause of cancer-related deaths globally.The increased mortality rate of ESCC patients is predominantly due to the advanced stage of the disease when discovered,coupled with higher risk of metastasis,which is an exceedingly malignant charac-teristic of cancer,frequently leading to a high mortality rate.Unfortunately,there is currently no specific and effective marker to predict and treat metastasis in ESCC.MicroRNAs(miRNAs)are a class of small non-coding RNA molecules,approximately 22 nucleotides in length.miRNAs are vital in modulating gene expression and serve pivotal regulatory roles in the occurrence,progression,and prognosis of cancer.Here,we have examined the literature to highlight the intimate correlations between miRNAs and ESCC metastasis,and show that ESCC metastasis is predominantly regulated or regulated by genetic and epigenetic factors.This review proposes a potential role for miRNAs as diagnostic and therapeutic biomarkers for metastasis in ESCC metastasis,with the ultimate aim of reducing the mortality rate among patients with ESCC.

Targeting therapy for hepatocellular carcinoma by delivering microRNAs as exosomal cargo

Exosomes,the smallest extracellular vesicles,have gained significant attention as key mediators in intercellular communication,influencing both physiological and pathological processes,particularly in cancer progression.A recent review article by Wang et al was published in a timely manner to stimulate future research and facilitate practical developments for targeted treatment of hepatocellular carcinoma using exosomes,with a focus on the origin from which exosomes derive.If information about the mechanisms for delivering exosomes to specific cells is incorporated,the concept of targeted therapy for hepatocellular carcinoma using exosomes could be more comprehensively understood.

Multifaceted role of microRNAs in gastric cancer stem cells: Mechanisms and potential biomarkers

MicroRNAs(miRNAs)have received much attention in the past decade as potential key epigenomic regulators of tumors and cancer stem cells(CSCs).The abnormal expression of miRNAs is responsible for different phenotypes of gastric cancer stem cells(GCSCs).Some specific miRNAs could be used as promising biomarkers and therapeutic targets for the identification of GCSCs.This review summarizes the coding process and biological functions of miRNAs and demon-strates their role and efficacy in gastric cancer(GC)metastasis,drug resistance,and apoptosis,especially in the regulatory mechanism of GCSCs.It shows that the overexpression of onco-miRNAs and silencing of tumor-suppressor miRNAs can play a role in promoting or inhibiting tumor metastasis,apart from the initial formation of GC.It also discusses the epigenetic regulation and potential clinical applications of miRNAs as well as the role of CSCs in the pathogenesis of GC.We believe that this review may help in designing novel therapeutic approaches for GC.

Emerging roles of microRNAs as diagnostics and potential therapeutic interest in type 2 diabetes mellitus

BACKGROUND Type 2 diabetes mellitus(T2DM)is a metabolic disease of impaired glucose utilization.Uncontrolled high sugar levels lead to advanced glycation end products(AGEs),which affects several metabolic pathways by its receptor of advanced glycation end products(RAGE)and causes diabetic complication.MiRNAs are small RNA molecules which regulate genes linked to diabetes and affect AGEs pathogenesis,and target tissues,influencing health and disease processes.AIM To explore miRNA roles in T2DM's metabolic pathways for potential therapeutic and diagnostic advancements in diabetes complications.METHODS We systematically searched the electronic database PubMed using keywords.We included free,full-length research articles that evaluate the role of miRNAs in T2DM and its complications,focusing on genetic and molecular disease mechanisms.After assessing the full-length papers of the shortlisted articles,we included 12 research articles.RESULTS Several types of miRNAs are linked in metabolic pathways which are affected by AGE/RAGE axis in T2DM and its complications.miR-96-5p,miR-7-5p,miR-132,has_circ_0071106,miR-143,miR-21,miR-145-5p,and more are associated with various aspects of T2DM,including disease risk,diagnostic markers,complications,and gene regulation.CONCLUSION Targeting the AGE/RAGE axis,with a focus on miRNA regulation,holds promise for managing T2DM and its complications.MiRNAs have therapeutic potential as they can influence the metabolic pathways affected by AGEs and RAGE,potentially reducing inflammation,oxidative stress,and vascular complications.Additionally,miRNAs may serve as early diagnostic biomarkers for T2DM.Further research in this area may lead to innovative therapeutic strategies for diabetes and its associated complications.

microRNAs在儿童呼吸道合胞病毒感染中调控作用的研究进展

呼吸道合胞病毒(RSV)是儿童急性下呼吸道感染最常见的病原体,对儿童的健康构成严重威胁,但其病理机制仍不明确,目前仍然没有有效预防和治疗呼吸道合胞病毒的方法。RSV是具有包膜单负链RNA病毒,编码11种蛋白质,这些蛋白质是诱导气道高反应性(AHR)的关键因素。微小RNA(miRNAs)近来被认为是基因表达调控因子,通过调节炎症反应和免疫细胞功能以及气道上皮细胞的宿主免疫反应,在病毒感染中发挥调控作用。本文综述了miRNAs在RSV感染中调控作用的研究进展,旨在为RSV的致病机制、诊断及治疗提供新思路。

microRNAs在呼吸道合胞病毒感染中作用的研究进展

呼吸道合胞病毒是儿童急性下呼吸道感染最常见的病原体,严重威胁儿童健康,其致病机制较为复杂,目前仍然没有有效预防和治疗呼吸道合胞病毒的方法。近年来,miRNA在调节基因表达和蛋白质功能中的作用受到了广泛关注,很多的证据表明miRNA在呼吸道合胞病毒感染的调控中发挥着重要作用。本文综述了miRNA在呼吸道合胞病毒感染中调控作用的研究进展,旨在为呼吸道合胞病毒的致病机制研究、诊断及治疗提供新思路。

Current Research Status of MicroRNAs in Squamous Cell Carcinoma of the Tongue

Tongue squamous cell carcinoma (TSCC) is the most invasive type of oral malignant tumor, posing a serious threat to human life and health. Its pathogenesis is complex and has a high degree of malignancy. Recurrence and metastasis often lead to poor prognosis. MicroRNAs are a type of single stranded small molecule RNA with only 18 - 25 nucleotides, which can regulate the expression of various genes and participate in the occurrence and development of tumors. Studies have found that microRNA expression profiling can serve as a reliable and stable biological indicator for early diagnosis and prognosis of tumors. This article provides a review of the research status of MicroRNAs in squamous cell carcinoma of the tongue.

MicroRNAs在脑缺血后大脑神经保护中的作用

脑卒中是世界范围内导致身体残疾和死亡的主要原因之一,其中缺血性脑卒中占卒中的80%以上。一旦发生脑卒中,90%的幸存者遗有轻到重度的永久性神经功能障碍,给家庭和社会带来沉重的经济和精神负担。因此,有效促进缺血性脑卒中后各种神经功能的恢复成为临床医学和基础医学研究的重点和热点。

microRNAs在帕金森病发病机制中作用研究进展

帕金森病(Parkinson’s disease)发病机制复杂,多种机制已被证明与帕金森病的病理生理机制有关,如α-突触核蛋白的积累、氧化应激、异常细胞凋亡和神经炎症等。微小RNA(MicroRNA,miRNA)是一种由内源性基因编码的非编码单链RNA分子。在过去的十年里,许多研究报道了miRNA在一系列重要的生命过程中发挥作用。此外,大量的动物模型实验和临床研究也发现了miRNA在帕金森病中的失调,并证明miRNA通过不同的途径在帕金森病的发生发展中发挥了重要作用。本文综述了一些参与帕金森病发生发展的重要miRNAs。

MicroRNAs在妇科肿瘤发生发展中的研究进展

microRNAs(miRNAs)是一类小RNA分子,在植物和动物的基因表达调控中发挥着重要作用,miRNAs不参与蛋白质的直接合成,而是转录后基因表达的重要调控因子。它们不仅在身体发育中起着关键作用,也是细胞周期、凋亡和分化的关键调节因子。成熟miRNAs的产生需要几个关键步骤。首先,在细胞核中经由RNA polymerase II(PolII)转录完成聚腺苷酸化和封顶产生primary mi RNAs(Pri-miRNAs)。Pri-miRNAs通过Drosha/DGCR8复合物进一步加工合成hairpin precursor mi RNAs(pre-miRNAs)。Pre-miRNAs通过输出蛋白5(XPO5)输出到细胞质中,并被Dicer切割,在这一过程进行末端环的切割后形成成熟的miRNAs。miRNAs以互补序列结合靶mRNA,发挥调控作用。研究表明,超过30%的蛋白质编码基因受miRNAs调控。miRNAs的失调和功能障碍与人类疾病有关,miRNAs的异常表达被认为是癌症发生的重要过程。本文就microRNAs在妇科肿瘤发生发展中的研究现状进行综述。

MicroRNAs in hepatocellular carcinoma treatment:Charting the path forward

MicroRNAs(miRNAs)are recognized for their involvement in the regulation of gene expression and exhibit significant potential in both the prognostic assessment and treatment of hepatocellular carcinoma(HCC).HCC,like other tumors,seldom occurs in isolation;instead,it evolves within a microenvironment featuring oncogenic and tumor-suppressive elements.When combined with suitable delivery vehicles,miRNA technology provides the capability to directly engage with these elements,thereby hindering tumor formation and progression.Ongoing research in this domain holds the promise of enabling a more efficacious and multi-modal treatment approach for HCC in the near future.

MicroRNAs as potential biomarkers for diagnosis of attention deficit hyperactivity disorder

Inappropriate levels of hyperactivity,impulsivity,and inattention characterize attention deficit hyperactivity disorder,a common childhood-onset neuropsychiatric disorder.The cognitive function and learning ability of children with attention deficit hyperactivity disorder are affected,and these symptoms may persist to adulthood if they are not treated.The diagnosis of attention deficit hyperactivity disorder is only based on symptoms and objective tests for attention deficit hyperactivity disorder are missing.Treatments for attention deficit hyperactivity disorder in children include medications,behavior therapy,counseling,and education services which can relieve many of the symptoms of attention deficit hyperactivity disorder but cannot cure it.There is a need for a molecular biomarker to distinguish attention deficit hyperactivity disorder from healthy subjects and other neurological conditions,which would allow for an earlier and more accurate diagnosis and appropriate treatment to be initiated.Abnormal expression of microRNAs is connected to brain development and disease and could provide novel biomarkers for the diagnosis and prognosis of attention deficit hyperactivity disorder.The recent studies reviewed had performed microRNA profiling in whole blood,white blood cells,blood plasma,and blood serum of children with attention deficit hyperactivity disorder.A large number of microRNAs were dysregulated when compared to healthy controls and with some overlap between individual studies.From the studies that had included a validation set of patients and controls,potential candidate biomarkers for attention deficit hyperactivity disorder in children could be miR-140-3p,let-7g-5p,-30e-5p,-223-3p,-142-5p,-486-5p,-151a-3p,-151a-5p,and-126-5p in total white blood cells,and miR-4516,-6090,-4763-3p,-4281,-4466,-101-3p,-130a-3p,-138-5p,-195-5p,and-106b-5p in blood serum.Further studies are warranted with children and adults with attention deficit hyperactivity disorder,and consideration should be given to utilizing rat models of attention deficit hyperactivity disorder.Animal studies could be used to confirm microRNA findings in human patients and to test the effects of targeting specific microRNAs on disease progression and behavior.

microRNAs对心脏电生理特性影响的研究进展

非心脏外科围术期心律失常的发生率4%~20%,而心胸外科围术期心律失常的发生率为10%~30%,其中心脏手术患者围术期心律失常的发生率高达90%。围术期心律失常可延长住院时间,增加患者住院期间的发病率和死亡率。研究表明,心血管疾病中存在的异常表达microRNAs可通过调控离子通道、缝隙连接蛋白及细胞内Ca2+处理蛋白等,参与心脏自律性、兴奋性以及传导性,从而调节心脏电生理稳态和心律失常。本文将主要从心脏电生理失衡的角度综述microRNA与心律失常的研究进展。

MicroRNAs as potential diagnostic biomarkers for bipolar disorder

Abnormal expression of microRNAs is connected to brain development and disease and could provide novel biomarkers for the diagnosis and prognosis of bipolar disorder. We performed a PubMed search for microRNA biomarkers in bipolar disorder and found 18 original research articles on studies performed with human patients and published from January 2011 to June 2023. These studies included microRNA profiling in bloodand brain-based materials. From the studies that had validated the preliminary findings,potential candidate biomarkers for bipolar disorder in adults could be miR-140-3p,-30d-5p,-330-5p,-378a-5p,-21-3p,-330-3p,-345-5p in whole blood, miR-19b-3p,-1180-3p,-125a-5p, let-7e-5p in blood plasma, and miR-7-5p,-23b-5p,-142-3p,-221-5p,-370-3p in the blood serum. Two of the studies had investigated the changes in microRNA expression of patients with bipolar disorder receiving treatment. One showed a significant increase in plasma miR-134 compared to baseline after 4 weeks of treatment which included typical antipsychotics, atypical antipsychotics, and benzodiazepines. The other study had assessed the effects of prescribed medications which included neurotransmitter receptorsite binders(drug class B) and sedatives, hypnotics, anticonvulsants, and analgesics(drug class C) on microRNA results. The combined effects of the two drug classes increased the significance of the results for miR-219 and-29c with miR-30e-3p and-526b* acquiring significance. MicroRNAs were tested to see if they could serve as biomarkers of bipolar disorder at different clinical states of mania, depression, and euthymia. One study showed that upregulation in whole blood of miR-9-5p,-29a-3p,-106a-5p,-106b-5p,-107,-125a-3p,-125b-5p and of miR-107,-125a-3p occurred in manic and euthymic patients compared to controls, respectively, and that upregulation of miR-106a-5p,-107 was found for manic compared to euthymic patients. In two other studies using blood plasma,downregulation of miR-134 was observed in manic patients compared to controls, and dysregulation of miR-134,-152,-607,-633,-652,-155 occurred in euthymic patients compared to controls. Finally, microRNAs such as miR-34a,-34b,-34c,-137, and-140-3p,-21-3p,-30d-5p,-330-5p,-378a-5p,-134,-19b-3p were shown to have diagnostic potential in distinguishing bipolar disorder patients from schizophrenia or major depressive disorder patients, respectively. Further studies are warranted with adolescents and young adults having bipolar disorder and consideration should be given to using animal models of the disorder to investigate the effects of suppressing or overexpressing specific microRNAs.

基于microRNAs差异分析和网络药理学探讨益母草治疗宫腔粘连相关机制

目的通过microRNAs差异分析、网络药理学及分子对接技术,探讨益母草治疗宫腔粘连(intrauterine adhesion,IUA)的潜在作用靶点及相关机制。方法基于GEO(gene expression omnibus)数据库筛选IUA与健康者的差异miRNA,经multiMiR进行靶基因预测。通过TCMSP(traditional Chinese medicine systems pharmacology)数据库检索益母草有效活性成分及相关靶点,并与miRNA靶基因取交集。利用String平台进行蛋白质互作分析,利用cytoNCA筛选关键靶点。基于R语言进行基因本体(gene ontology,GO)和基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)富集分析。利用CB-dock2对关键靶点和活性成分进行分子对接。结果共筛选出与IUA相关的差异miRNA 43个,经靶基因预测后与IUA共有13个交集靶点,GO及KEGG富集分析结果显示,益母草治疗IUA作用机制主要与细胞衰老、丝裂原活化蛋白激酶(mitogen-activated protein kinase,MAPK)信号通路、PI3K-Akt信号通路等有关。益母草3个特征性活性成分是花生四烯酸、山奈酚、槲皮素,可与蛋白互作网络中相对应的靶点蛋白细胞周期蛋白依赖性激酶4(cyclin-dependent kinase 4,CDK4)、芳香烃受体(aryl hydrocarbon receptor,AHR)、原癌基因c-myc编码转录因子、血管内皮生长因子(vascular endothelial growth factor,VEGF)进行分子对接,主要活性成分能够与核心靶点结合,并展现出较好的亲和力。结论益母草治疗IUA是多成分、多靶点、多通路相互作用的结果,进一步证实了益母草治疗IUA的科学性及有效性,为后续实验提供了研究思路。

基于microRNAs差异分析和网络药理学预测左归丸化裁方治疗早发性卵巢功能不全相关机制

目的基于五脏理论,通过基因差异分析、网络药理学及分子对接技术,初步预测左归丸化裁方在治疗早发性卵巢功能不全(premature ovarian insufficiency,POI)过程中对microRNAs的干预作用,分析潜在的作用靶点及可能的作用机制,通过动物实验验证部分靶点。方法基于GEO数据库筛选POI与健康人的差异miRNA,经Funrich 3.1.3进行靶基因预测。TCMSP数据库检索左归丸化裁方中有效活性成分及相关靶点,并与miRNA靶基因取交集。利用STRING平台进行蛋白质互作分析,根据拓扑参数筛选关键靶点。基于Metascape数据库进行基因本体(gene ontology,GO)和基因组百科全书(kyoto encyclopedia of genes and genomes,KEGG)分析。利用Autodock vina 1.1.2软件对关键靶点和活性成分进行半柔性对接。动物实验验证部分预测结果。结果共筛选出30个与POI差异表达的miRNA,经靶基因预测后,与左归丸化裁方共有65个交集靶点,涉及156个有效活性成分,参与细胞老化、氧化应激、蛋白质转运调节肽基丝氨酸磷酸化、炎症调节、卵泡发育等多种生物学过程,涉及AGE-RAGE、TNF、雌激素、IL-17、HIF-1、PI3K-Akt、foxo、VEGF等37个信号通路。分子对接结果示β-谷固醇、丹参酮、木犀草素、豆甾醇等核心成分与部分关键靶点有较强的结合能力。动物实验证明,左归丸化裁方可通过上调Akt、PI3K、VEGF、TGF-β1及CTGF,下调PTEN的表达有效改善卵巢功能(P<0.05),验证了网络药理学部分预测结果。结论左归丸化裁方可多成分、多基因、多靶点、多通路治疗POI,为进一步的研究提供思路及依据。